Laboratorios Stein was founded in Costa Rica, laying the foundations of a healthcare company with a strong regional vision. During its early years, the company expanded across Central America, building a solid Primary Care portfolio and establishing its operational footprint in the region.

SteinCares was created as the Specialty Care division of Laboratorios Stein and rapidly evolved into the group’s main growth engine.

With a clear focus on addressing Latin America’s most pressing healthcare needs, SteinCares began bringing global innovation to the region through strategic partnerships and differentiated capabilities.

Key milestones during this phase include:

• First to market biosimilars in Central America and Ecuador, in partnership with Celltrion.
• Entry into innovative therapeutic areas through global alliances, including Gilead.
• Strategic divestment of the Primary Care portfolio to Eurofarma, enabling full focus on Specialty Care.

As part of its long-term transformation, SteinCares became the core business of the group, supported by a series of strategic decisions to accelerate growth and strengthen its regional platform.

Some of our recent milestones include:

• Sale of the Cartago manufacturing facility to reinforce our partnership-driven model.
• IFC (International Finance Corporation) joining as a minority shareholder
• Strategic acquisitions in Chile and Colombia, entry into Brazil and a Joint Venture in Mexico
• New licensing agreements in biosimilars and innovative segments.